{
    "clinical_study": {
        "@rank": "149776", 
        "arm_group": [
            {
                "arm_group_label": "Idelalisib+bendamustine+rituximab", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive idelalisib for 96 weeks, bendamustine for 6 months, and rituximab for 6 months."
            }, 
            {
                "arm_group_label": "Idelalisib placebo+bendamustine+rituximab", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants will receive placebo to match idelalisib for 96 weeks, bendamustine for 6 months, and rituximab for 6 months."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the effect of the addition of idelalisib to bendamustine and\n      rituximab on minimal residual disease (MRD) and evaluate the progression-free survival (PFS)\n      in participants with previously untreated chronic lymphocytic leukemia (CLL)."
        }, 
        "brief_title": "Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia", 
        "completion_date": {
            "#text": "January 2022", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Lymphocytic Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Documented diagnosis of B-cell CLL, with diagnosis established according to\n             International Workshop on Chronic Lymphocytic Leukemia (IWCLL)\n\n          -  No prior therapy for CLL other than corticosteroids for disease complications\n\n          -  CLL that warrants treatment\n\n          -  Presence of measurable lymphadenopathy\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of \u2264 2\n\n        Exclusion Criteria\n\n          -  Known histological transformation from CLL to an aggressive lymphoma (ie, Richter\n             transformation)\n\n          -  Known presence of myelodysplastic syndrome\n\n          -  Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of\n             randomization\n\n          -  Ongoing liver injury\n\n          -  Ongoing drug-induced pneumonitis\n\n          -  Ongoing inflammatory bowel disease\n\n          -  History of prior allogeneic bone marrow progenitor cell or solid organ\n             transplantation\n\n          -  Ongoing immunosuppressive therapy other than corticosteroids\n\n          -  Concurrent participation in another therapeutic clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "280", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01980888", 
            "org_study_id": "GS-US-312-0123", 
            "secondary_id": "2013-003313-17"
        }, 
        "intervention": [
            {
                "arm_group_label": "Idelalisib+bendamustine+rituximab", 
                "description": "Idelalisib 100 mg or 150 mg tablets administered orally twice daily", 
                "intervention_name": "Idelalisib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "GS-1101", 
                    "CAL-101"
                ]
            }, 
            {
                "arm_group_label": [
                    "Idelalisib+bendamustine+rituximab", 
                    "Idelalisib placebo+bendamustine+rituximab"
                ], 
                "description": "Bendamustine 25 mg or 100 mg administered intravenously at a starting dose of 90 mg/m2", 
                "intervention_name": "Bendamustine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Idelalisib+bendamustine+rituximab", 
                    "Idelalisib placebo+bendamustine+rituximab"
                ], 
                "description": "Rituximab 100 mg or 500 mg single-use vials administered intravenously weekly starting at 375 mg/m2 on Day 1 (Week 0) and 500 mg/m2 thereafter", 
                "intervention_name": "Rituximab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Idelalisib placebo+bendamustine+rituximab", 
                "description": "Placebo to match idelalisib administered orally twice daily", 
                "intervention_name": "Idelalisib placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bendamustine", 
                "Rituximab", 
                "Nitrogen Mustard Compounds"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 17, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Eibrahim@epiclp.com", 
                    "last_name": "Emad Ibrahim, MD", 
                    "phone": "909-425-3372"
                }, 
                "facility": {
                    "address": {
                        "city": "Highland", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92346"
                    }, 
                    "name": "Beaver Medical Group, L.P."
                }, 
                "investigator": {
                    "last_name": "Emad Ibrahim, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ragajanian@airesearch.us", 
                    "last_name": "Richy Agajanian", 
                    "phone": "562-693-4477"
                }, 
                "facility": {
                    "address": {
                        "city": "Whittier", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90603"
                    }, 
                    "name": "Innovative Clinical Research Institute"
                }, 
                "investigator": {
                    "last_name": "Richy Agajanian, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mjt2716@sbcglobal.net", 
                    "last_name": "Mark J Turney", 
                    "phone": "860-621-9316"
                }, 
                "facility": {
                    "address": {
                        "city": "Southington", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06489"
                    }, 
                    "name": "Cancer Center of Central Connecticut"
                }, 
                "investigator": {
                    "last_name": "Peter Byeff, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mehdi.moezi@CSNF.US", 
                    "last_name": "Mehdi Moezi", 
                    "phone": "904-264-6201"
                }, 
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32256"
                    }, 
                    "name": "Cancer Specialists of North Florida"
                }, 
                "investigator": {
                    "last_name": "Mehdi Moezi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mzayden@hotmail.com", 
                    "last_name": "Muhammad Zaydan", 
                    "phone": "859-499-1000"
                }, 
                "facility": {
                    "address": {
                        "city": "Mount Sterling", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40353"
                    }, 
                    "name": "Montgomery Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Muhammad Zaydan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rboccia@ccbdmd.com", 
                    "last_name": "Ralph Boccia", 
                    "phone": "301-571-0019"
                }, 
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20817"
                    }, 
                    "name": "Center for Cancer and Blood Disorders"
                }, 
                "investigator": {
                    "last_name": "Ralph Boccia, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mmackenzie@hoannj.com", 
                    "last_name": "Charles Farber", 
                    "phone": "973-538-5210"
                }, 
                "facility": {
                    "address": {
                        "city": "Morristown", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07962"
                    }, 
                    "name": "Hematology /Oncology Associates of Northern New Jersey"
                }, 
                "investigator": {
                    "last_name": "Charles Farber, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "research@gabrailcancercenter.com", 
                    "last_name": "Nashat Gabrail", 
                    "phone": "330-492-3345"
                }, 
                "facility": {
                    "address": {
                        "city": "Canton", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44718"
                    }, 
                    "name": "Gabrail Cancer Center Research"
                }, 
                "investigator": {
                    "last_name": "Nashat Gabrail, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nvrindavanam@cinci.rr.com", 
                    "last_name": "Nandagopal Vrindavanam", 
                    "phone": "513-217-4809"
                }, 
                "facility": {
                    "address": {
                        "city": "Middletown", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45042"
                    }, 
                    "name": "Signal Point Clinical Research Center"
                }, 
                "investigator": {
                    "last_name": "Nandagopal Vrindavanam, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Howland_Croswell@bshsi.org", 
                    "last_name": "Howland Crosswell, MD", 
                    "phone": "864-546-3699"
                }, 
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29601"
                    }, 
                    "name": "Saint Francis Hospital"
                }, 
                "investigator": {
                    "last_name": "Howland Crosswell, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bipin.amin@prairielakes.com", 
                    "last_name": "Amin Bipinkumar", 
                    "phone": "605-882-6800"
                }, 
                "facility": {
                    "address": {
                        "city": "Watertown", 
                        "country": "United States", 
                        "state": "South Dakota", 
                        "zip": "57201"
                    }, 
                    "name": "Prairie Lakes Healthcare System Inc."
                }, 
                "investigator": {
                    "last_name": "Amin Bipinkumar, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia", 
        "overall_contact": {
            "email": "michelle.wong@gilead.com", 
            "last_name": "Michelle Wong"
        }, 
        "overall_contact_backup": {
            "email": "susan.guillet@gilead.com", 
            "last_name": "Susan Guillet"
        }, 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Henry Adewoye, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "Bulgaria: Bulgarian Drug Agency", 
                "Canada: Health Canada", 
                "Croatia: Agency for Medicinal Product and Medical Devices", 
                "Czech Republic: State Institute for Drug Control", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines", 
                "Italy: The Italian Medicines Agency", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Portugal: INFARMED, National Authority of Medicines and Health Products, IP", 
                "Romania: National Agency for Medicines and Medical Devices", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Minimal residual disease (MRD) negativity rate is defined as the proportion of subjects with MRD < 10^-4 assessed by flow cytometry in bone marrow at Week 36 after therapy initiation or at least 12 weeks after the last dose of rituximab for participants receiving the final dose of rituximab after the original scheduled date.", 
                "measure": "Minimal residual disease negativity rate", 
                "safety_issue": "No", 
                "time_frame": "Week 36"
            }, 
            {
                "description": "Progression-free survival (PFS) is defined as the interval from randomization to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone.", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Year 8"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01980888"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall response rate (ORR) is defined as the proportion of participants who achieve a complete or partial response.", 
                "measure": "Overall response rate", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Year 8"
            }, 
            {
                "description": "Nodal response rate is defined as the proportion of participants who achieve a 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions.", 
                "measure": "Nodal response rate", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Year 8"
            }, 
            {
                "description": "Complete response rate is defined as the proportion of participants who achieve a complete response.", 
                "measure": "Complete response rate", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Year 8"
            }, 
            {
                "description": "Overall survival is defined as the interval from randomization to death from any cause.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Year 8"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}